Trial Profile
Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe/simvastatin (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Acronyms BRAVO
- Sponsors Organon
- 25 Aug 2010 Actual initiation date changed from Jan 2007 to Aug 2007 as reported by ClinicalTrials.gov.
- 25 Aug 2010 Actual end date changed from Feb 2009 to Jul 2009 as reported by ClinicalTrials.gov.
- 04 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.